# CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

> **NCT03029338** · PHASE1 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 20 (actual)

## Conditions studied

- Lymphomas Non-Hodgkin's B-Cell
- Relapse

## Interventions

- **BIOLOGICAL:** CD19 CAR T cells

## Key facts

- **NCT ID:** NCT03029338
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-08
- **Primary completion:** 2019-05-22
- **Final completion:** 2021-06-22
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- Juventas Cell Therapy Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029338, "CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma". Retrieved via AI Analytics 2026-05-18 from https://api.ai-analytics.org/clinical/NCT03029338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*